Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update The financial statements for the first half of 2019 reflect operating results of -€5.3 million, compared to -€6.8 million one year earlier due to decreased expenses relating to the end of the NEW-HOPE Phase IIb trial. Read the press release Previous Post (p) Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure Next Post (n) Quantum Genomics and Biolab Sanus Pharmaceutical have signed an exclusive agreement for firibastat in Latin America